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Introduction. Germline aryl hydrocarbon receptor-interacting protein (AIP) mutations are responsible for 15–30% of familial
isolated pituitary adenomas (FIPAs). We report a FIPA kindred with a heterozygous deletion in AIP, aiming to highlight the
indications and beneﬁts of genetic screening, variability in clinical presentations, and management challenges in this setting.
Patients. An 18-year-old male was diagnosed with a clinically nonfunctioning pituitary adenoma (NFPA). Two years later, his
brother was diagnosed with a somatolactotrophinoma, and a small Rathke’s cleft cyst and a microadenoma were detected on
screening in their 17-year-old sister. Following amenorrhoea, their maternal cousin was diagnosed with hyperprolactinaemia
and two distinct pituitary microadenomas. A 12-year-old niece developed headache and her MRI showed a microadenoma, not
seen on a pituitary MRI scan 3 years earlier. Discussion. Out of the 14 members harbouring germline AIP mutations in this
kindred, 5 have pituitary adenoma. Aﬀected members had diﬀerent features and courses of disease. Bulky pituitary and not fully
suppressed GH on OGTT can be challenging in the evaluation of females in teenage years. Multiple pituitary adenomas with
diﬀerent secretory proﬁles may arise in the pituitary of these patients. Small, stable NFPAs can be present in mutation carriers,
similar to incidentalomas in the general population. Genetic screening and baseline review, with follow-up of younger subjects,
are recommended in AIP mutation-positive families.
1. Introduction
Pituitary adenomas (PAs) are benign tumours with a high
prevalence in autopsy and radiological studies, ranging from
14.4 up to 22.5% [1]. However, clinically relevant PAs are sig-
niﬁcantly less common, aﬀecting 1 : 1064 up to 1 : 1470 of the
general population [2–6]. The great majority of PAs occur
sporadically, but around 5% are familial in origin, which
either occur as part of a syndrome, such as in multiple endo-
crine neoplasia type 1 (MEN1) andMEN4 or in Carney com-
plex, or can be isolated to the pituitary as in familial isolated
pituitary adenomas (FIPAs). FIPA kindreds are recognised
when 2 or more family members display PAs in the absence
of other syndromic features.
In 2006, loss-of-function mutations in the aryl hydrocar-
bon receptor-interacting protein (AIP) gene were recognised
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as predisposing for PAs [7]. The gene encoding the AIP pro-
tein is located on chromosome 11q13.3, and to date, over 70
AIP mutations have been described. Truncating mutations
account for the majority of AIP mutations [8–10]. Germline
heterozygous AIPmutations are responsible for 20% of FIPA
[10] and can be identiﬁed in 3-4% of unselected sporadic PAs
[11, 12], 20.5% of childhood-onset PAs, 11.7% of pituitary
macroadenomas in young patients (<30 years) [13], and
around 7% of PAs diagnosed in patients under the age of
40 with no known family history of pituitary disease [11].
Growth hormone- (GH-) secreting and GH- and prolactin-
cosecreting PAs dominate, but prolactinomas, nonfunction-
ing PA (NFPA), and few ACTH- and TSH-secreting PAs
were also described. PAs in patients with AIP mutations
present earlier in life and are larger, more invasive, and less
responsive to treatment [8, 10].
In this paper, we describe in detail a large four-generation
FIPA kindred with a heterozygous AIP gene deletion, dis-
cussing a variety of clinical scenarios and common manage-
ment challenges and highlighting the genetic screening
beneﬁts in this setting. Taking together our clinical experi-
ence and published data on this condition, we aim to answer
relevant questions in order to aid clinicians in the recogni-
tion, diagnosis, and management of this condition. More-
over, we give voice to patients and carriers by including a
section with their own comments regarding their condition;
in our opinion, this is helpful for understanding the perspec-
tives and needs in this setting of patients.
2. Case 1 (Proband)
The proband, an 18-year-old male, presented in 2000 with a
3-month history of lethargy, daytime sleepiness, exhaustion,
loss of appetite, and headaches, few months after his
mother’s death due to a spinal ependymoma. These com-
plaints were initially attributed to grief, but their worsening
lead to an endocrine investigation, which revealed secondary
adrenal failure (9 am serum cortisol: 68 nmol/L, undetectable
ACTH), secondary hypothyroidism (FT4< 5.1 pmol/L [9.4–
24.0], TSH: 1.56mU/L), hyperprolactinaemia (prolactin:
1466mU/L [45–375]), “borderline” secondary hypogonad-
ism (LH: 1.3mU/L [0.8–6.1], FSH: 2.3mU/L [1.6–11.0],
and morning total testosterone: 13.0 nmol/L [13–40]), and
normal IGF-1 close to the upper limit of the reference range
(61.9 nmol/L [29–64]). Basal GH or oral glucose tolerance
test (OGTT) were not performed. The remaining blood tests,
including serum calcium, were normal. His pituitary MRI
demonstrated a pituitary macroadenoma with cavernous
sinus invasion and suprasellar extension, impinging and
displacing the optic chiasma. He had normal visual ﬁelds,
normal height (178.2 cm, midparental height: 174.5 cm),
and no symptoms of acromegaly. He was diagnosed with a
clinically nonfunctioning pituitary adenoma, although an
IGF-1 at the upper limit of the reference range, in the pres-
ence of a macroadenoma with partial hypopituitarism, raises
the possibility of a poorly secreting somatotropinoma. He
underwent transsphenoidal surgery (TSS), and the histology
showed a chromophobe adenoma with scattered single GH-
positive cells and a few clusters of prolactin-positive cells,
with the Ki67 index estimated at 5–10%. Seventeen years
after the diagnosis, he is well on thyroxine replacement, dis-
playing normal IGF-1 and prolactin, and his recent MRI
scan showed no recurrent tumour growth, with a visible thin
rim of tissue around the walls of his large pituitary fossa that
is stable since his ﬁrst postoperative scan (Figure 1(a)).
3. Case 2
The proband’s brother presented in 2002 at the age of 18
years with a 2-month history of frontal headaches and leth-
argy. Clinical examination revealed tall stature (184.5 cm,
midparental height: 174.5 cm). GH excess was documented
by an elevated IGF-1 (75.3 nmol/L [29–64]) and a random
GH(54μg/L);OGTTGHnadirwas 0.4μg/L (Table 1).Hyper-
prolactinaemia (927mU/L [45–375]) and secondary hypo-
thyroidism (FT4: 7.3 pmol/L [9.4–24.0], TSH: 0.7mU/L)
were also noted, and secondary adrenal failure was excluded
by a short Synacthen test (baseline cortisol: 223 nmol/L,
peak: 467 nmol/L). Pituitary MRI showed a macroadenoma
with suprasellar extension and impingement on the optic chi-
asm, but no cavernous sinus invasion (Figure 1(b)). A small
left upper temporal ﬁeld deﬁciency was detected. He under-
went TSS, and the histology showed a sparsely granulated
somatotroph adenomawith strong expression ofGHandpro-
lactin and 10–20%LH- and FSH-positive cells. For the next 13
years after TSS, he had ongoing headaches, but no
acromegaly-related complaints. A small 5mm region with
reduced enhancement was visible in the pituitary fossa, possi-
bly representing adenoma remnant (Figure 1(c)), unchanged
over those years. He was eupituitary, and during follow-up,
his somatotrope axis evaluation was consistent with mild
and intermittent biochemical evidence of GH excess (IGF-1
ranging between 168 and 398μg/L and incomplete GH sup-
pression on OGTT (Table 1)). Considering that he was
asymptomatic and reluctant to havemedical therapy, awatch-
ful waiting approach was taken. However, since 2015, he
became sweaty with occasional joint pain, and his IGF-1
raised at 1.4×ULN, with an OGTT GH nadir of 2.53μg/L
and a mean GH of 2.59μg/L on a day curve (Table 1). More-
over, a minimal increase in the remnant was reported on his
last MRI (Figure 1(d)). He was commenced on lanreotide
(120mg/every 4 weeks) but developed signiﬁcant gastrointes-
tinal side eﬀects, particularly nausea and diarrhoea. As bio-
chemical response was unsatisfactory, medication was
stopped and TSS was planned. Postoperative MRI showed
no residual tumour. His headache signiﬁcantly improved.
He is now on hydrocortisone, thyroxine, and testosterone
replacement. The histology of the excised remnant tumoural
lesion was similar to that of the ﬁrst operation, with Ki67 less
than 3%.
Headaches were always his main complaint and aﬀected
considerably his quality of life. He was reviewed by a head-
ache specialist in a clinic and also by an ear, nose, and throat
specialist who excluded sinusitis as a cause of his headaches.
The headaches occurred daily and were not associated with
migraine-like symptoms. They were triggered by exercise or
submersion, leading him to quit diving in summer. He
reported two diﬀerent types of headaches: dull daily
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headache and the other a sharp and short-lasting (20 seconds
to 1 minute) pain in the right side of his head, associated with
dizziness, but no nausea, vomiting, or photophobia. His
sharp right-sided headaches were diagnosed as paroxysmal
hemicrania, a form of trigeminal autonomic cephalalgia
[14], ipsilateral to the remnant, despite the absence of cav-
ernous sinus invasion. Short-acting octreotide (100μg three
times a day for a six weeks) and later cabergoline (250μg
three times a week) were tried in 2009 but have not changed
his headache considerably, based on his headache diary. On
short-acting octreotide, none of the GH measurements from
a GH day curve were undetectable, and his IGF-1 was
266ng/mL (Table 1). Headaches remained signiﬁcantly
improved after the second operation.
4. Case 3
Following the genetic diagnosis, the proband’s 17-year-old
carrier sister reported occasional headache but no symptoms
of GH excess. She displayed normal IGF-1 and OGTT GH
nadir consistently lower than 0.4μg/L (Table 2), although
not undetectable. She had no hyperprolactinaemic symp-
toms, and her prolactin levels have been normal, apart from
the last evaluation that is slightly elevated (601mU/L,
normal< 495). Her pituitary MRI when she was ﬁrst
screened showed a large bulky pituitary with a height of
9.2mm and an area of 4.4mm of reduced enhancement in
the midline, faintly hyperintense before the contrast, sugges-
tive of a Rathke’s cleft cyst, which regressed completely over
the period of 5 years. In addition, a 4mm adenoma was visi-
ble in the dorsal aspect of the right side of her pituitary,
which has been stable over the years (Figure 2).
5. Case 4
The proband’s maternal second cousin presented in 2003, at
an age of 27 years, with secondary amenorrhoea after cessa-
tion of oral contraceptives. Hyperprolactinaemia was found
(1232mU/L), and bromocriptine was started. On bromocrip-
tine, her menses became regular and her prolactin normal-
ised (65mU/L), but her IGF-1 was raised at 97 nmol/L
[23.0–49.6], and her GH was not suppressed on OGTT
(GH nadir 6.5μg/L) with little clinical features. Her MRI
identiﬁed two pituitary microadenomas, a 6mm adenoma
on the right and a 4mm adenoma on the left (Figure 3(a)).
She underwent TSS in 2004, where both adenomas were
resected. The right PA was a sparsely granulated GH ade-
noma while the left PA corresponded to a prolactinoma, as
(a) (b)
(c) (d)
Figure 1: (a) The proband’s (case 1) last MRI scan showing a visible thin rim of tissue around the pituitary fossa walls but no recurrent
tumour. (b) A pituitary MRI scan of the proband’s brother (case 2) at the time of diagnosis, showing a pituitary macroadenoma
impinging the optic chiasma. (c) Case 2’s follow-up MRI scan 7 years after the original surgery shows a small 5mm region with reduced
enhancement in the right side of the pituitary representing a remnant of the pituitary adenoma, which has recently grown slightly (d) and
was operated.
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Table 1: Biochemical evaluation of the somatotrope and prolactin axes in the proband’s brother (case 2), at diagnosis, postoperatively, and
during follow-up. TSS: transsphenoidal surgery; ×ULN: times above the upper limit of normal.
Date of biochemical evaluation IGF-1 Normal range Prolactin Normal range
GH on OGTT
0′–30′–60′–90′–120′–150′
February 2002
Preoperatively
75.3(1.2×ULN) 29–64 nmol/L 927 45–375mU/L 2.0–0.4–0.8–0.5–0.5 μg/L
August 2002
Six months postoperatively
34.7
(0.5×ULN)
29–64 nmol/L 239
2002–2009 Results not available
May 2009
317
(0.8×ULN)
117–358 ng/mL 193 <496mU/L 1.4–1.0–0.82–0.74–1.4–2.4 μg/L
October 2009
On short-acting octreotide
(100 μg three times a day)
266
(0.7×ULN)
117–358 ng/mL 261 <496mU/L 0.96–1.1–1.2–1.2–1.3 μg/L
November 2010
389
(1.1×ULN)
117–358 ng/mL 298 <496mU/L
December 2010
168
(0.5×ULN)
117–358 ng/mL 260 <496mU/L
July 2011
348
(1.0×ULN)
117–358 ng/mL 256 <496mU/L
December 2012
326
(0.9×ULN)
117–358 ng/mL <496mU/L 1.9–1.36–1.12–1.24–1.45–1.59 μg/L
May 2014
398
(1.3×ULN)
125–302 μg/L 297 <496mU/L
October 2015
303
(1.0×ULN)
125–302 μg/L 313 <324mU/L
October 2016
326
(1.4×ULN)
82.5–240.4 μg/L 353 <324mU/L
3.41–3.17–2.53–2.59–2.91–2.87 μg/L
GH day curve over 10 hours
3.12 μg/L, 1.93 μg/L, 2.05 μg/L,
3.23 μg/L, 2.61 μg/L. Mean GH=2.59 μg/L
January 2017
On lanreotide
320
(1.3×ULN)
82.5–240.4 μg/L
February 2017
On lanreotide
280
(1.2×ULN)
82.5–240.4 μg/L
August 2017
Two months after the
second TSS
112
(0.5×ULN)
82.5–240.4 μg/L
September 2017
93
(0.4×ULN)
82.5–240.4 μg/L 161 <324mU/L 0.41–0.34–0.32–0.30–0.25–0.41 μg/L
Table 2: Biochemical evaluation of the somatotrope and prolactin axes in the proband’s sister (case 3).
Date of biochemical evaluation IGF-1 Normal range Prolactin Normal range
GH on OGTT
0′–30′–60′–90′–120′–150′
November 2008 433 94–506 ng/mL 405 <496mU/L
August 2009 261 94–506 ng/mL 444 <496mU/L
February 2010 283 94–506 ng/mL 456 <496mU/L 1.1–0.35–0.21–0.16–0.83–5.81 μg/L
September 2010 164 94–506 ng/mL 329 <496mU/L
June 2011 333 94–506 ng/mL 349 <496mU/L
September 2012 172 94–506 ng/mL 312 <496mU/L 1.07–0.35–0.22–0.19–0.28–1.05 μg/L
October 2013 253 149–332 μg/L 408 <496mU/L 7.28–1.65–0.69–0.32–0.27–0.25 μg/L
July 2015 224 149–332 μg/L 365 <496mU/L 10.56–1.65–0.73–0.38–0.39–0.62 μg/L
December 2016 166 103.3–328.4 μg/L 601 <496mU/L 4.62–2.10–0.76–0.46–0.22–0.14 μg/L
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conﬁrmed by GH and prolactin staining on histological anal-
ysis (Figure 3(b)). Following surgery, she had two spontane-
ous pregnancies. She was discharged from the endocrine
clinic, but when the potential genetic background of her dis-
ease was identiﬁed, she was recalled for genetic testing and
the follow-up restarted after theAIPmutation detection. This
patient had no contact with the proband’s side of the family
since the death of the proband’s mother and family links were
discovered via the genetic clinic (Figure 4). Fourteen years
after her diagnosis, she has normal pituitary function and
normal IGF-1 and prolactin, and her MRI is also normal.
Her children are both asymptomatic carriers under paediatric
endocrine follow-up.
6. Case 5
Following the genetic cascade screening, the proband’s ﬁrst
cousin once removed was identiﬁed at the age of 7 years as
an AIP mutation carrier. Follow-up was started at a paediat-
ric endocrine clinic. She had no clinical symptoms and dis-
played a normal growth proﬁle. At her ﬁrst evaluation, her
height was 124.8 cm corresponding to the 76th height centile
(midparental height: 50th centile). Her baseline IGF-1 and
prolactin were normal (Table 3). At the age of 9, she started
complaining of headache partially refractory to analgesia
and which aﬀected her concentration and school work. A
pituitary MRI excluded any pituitary lesion (Figure 5(a)).
Her repeated hormonal proﬁle was normal (Table 3). There
is a family history of migraine.
Three years later (in 2017), at the age of 12 years, the
headache worsened and an MRI scan showed a 3mm area
of reduced enhancement on the right side of her pituitary
consistent with a small PA (Figure 5(b)). There were some
inﬂammatory changes in the left sphenoid air sinus, which
may be relevant given the history of headache. Concomi-
tantly, her serum prolactin was raised at 784mU/L (normal
(a) (b)
(c) (d)
(e) (f)
Figure 2: Pituitary MRI scans of the proband’s sister (case 3), showing a Rathke’s cleft cyst when ﬁrst screened at the age of 17 (a, b), which
completely disappeared in the following 5 years (c, d). A 4mmmicroadenoma became visible in the right side (e) of her bulky pituitary (f).
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range< 496), and repeated prolactin measurements three
months later, collected at 0 and 30 minutes after cannulation,
showed again slightly raised prolactin levels (667 and
652mU/L, resp.). Macroprolactinemia was excluded by poly-
ethylene glycol precipitation, and there are no other apparent
causes of hyperprolactinemia in this young patient. Of note,
there is also a family history of constitutional delay of growth
and puberty in her noncarrier 15-year-old brother who is
under investigation by a paediatric endocrinologist. Her
latest auxology and biochemical GH axis assessment at the
age of 13.0 years is normal (Table 3). Her current height is
151.4 cm (SDS: −0.6), and her height velocity is normal
(5.0 cm/year). Her thyroid function tests were normal. She
is now in early puberty (Tanner stage A2 B2 P4). In view of
her inherited predisposition for PA, this lesion likely repre-
sents a microprolactinoma. However, since she has now
commenced puberty and her prolactin is only marginally
raised and stable, dopamine agonist treatment has not been
(a)
Right adenoma
GH staining
Right adenoma
PRL staining
Left adenoma
GH staining
Left adenoma
PRL staining
(b)
Figure 3: (a) Pituitary MRI of the proband’s second cousin (case 4) showing right 6mm and left 4mm PAs. (b) Immunostaining of the right
(upper 2 panels) and left (lower 2 panels) PAs. The right adenoma shows strong GH and scattered prolactin staining. The lower panels show
the left adenoma containing adenoma tissue (A), which stains strongly for prolactin and shows only scattered GH staining, and normal
pituitary tissue (NP) which is visible in many GH-stained cells.
II.a
I.a
II.b
III.b III.c
IV.b
III.d
II.c II.d II.e II.f
III.e
IV.dIV.C
Gigantism
Acromegaly
Prolactinoma
NFPA
Tested, not AIP mut carrier
Clinically unaffected, AIP gene status unknown
AIP mut carrier
II.b
II.g
Case 4III.a
IV.a Case 5
Case 1 Case 2 Case 3
Figure 4: Pedigree tree.
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commenced. However, this will be reconsider if there is bio-
chemical or radiological evidence of tumour progression or
abnormal pubertal development.
7. Genetic Screening of This Kindred
At the time of the diagnosis of case 2 in 2002, MEN1 testing
was performed, although the phenotype was not typical.
Carney complex was ruled out based on clinical grounds.
Following the identiﬁcation of AIP mutations as predispos-
ing for PAs in 2006 [7], conventional exon-exon sequencing
of the AIP gene revealed no mutations. However, multiplex
ligation-dependent probe ampliﬁcation (MLPA) was per-
formed later [15], and a heterozygous AIP exon 2 deletion
(c.(99+1_100-1)_(279+1_280-1)del) was found in both
brothers, as previously reported [8, 9, 15]. This exon deletion
theoretically results in the in-frame ablation of 60 amino
acids (A34_K93del) that correspond to three quarters of
the FKBP12-like domain in the AIP protein and probably
results in signiﬁcant protein folding abnormality, if the
shortened abnormal RNA is not degraded by nonsense-
mediated decay [8, 15].
Cascade genetic screening identiﬁed 8 carriers (Figure 4).
Carriers underwent endocrine evaluation, and 2 of them
(case 3 and case 5) were diagnosed prospectively with PA.
Overall, of 14 members carrying germline AIP mutations in
this kindred (3/14 obligate carriers), 5 have PAs and 6 are
asymptomatic carriers undergoing follow-up (Figure 4).
The PA penetrance in this kindred is estimated at 36% (5/
14). The 5 members with PAs, 2 males and 3 females, were
all diagnosed at an age< 30 years; 3 presented clinically and
2 were diagnosed prospectively. There is variability in PA
phenotypes in this kindred: 2 clinically NFPA, 1 somatolac-
totrophinoma, 1 microprolactinoma, and a concomitant pro-
lactinoma and somatotrophinoma. At present, three patients
are in remission (case 1, case 2, and case 4), and two females
with pituitary microadenomas and mild prolactin elevation
are under follow-up (case 3 and case 5).
8. AIP Mutation Carriers
Six alive asymptomatic AIP mutation carriers are under
follow-up in the endocrine or paediatric endocrine clinics
(Figure 4). Two carrier children in the family (aged 11 and
8 years) show normal growth, IGF-I, and prolactin levels,
and 3 adult carriers have normal clinical, biochemical, and
MRI assessments. One carrier, the proband’s 45-year-old
male cousin, has no clinical symptoms and normal MRI,
but his IGF-1 was seen once slightly raised at 260nmol/L
[94–252] with an OGTT GH nadir of 0.28μg/L, with the rest
Table 3: Biochemical evaluation of the somatotrope and prolactin axes in the proband’s second cousin (case 5).
Date of biochemical evaluation IGF-1 Normal range Prolactin Normal range
GH on OGTT
0′–30′–60′–90′–120′–150′
March 2012 193 53–300 ng/mL 424 <496mU/L
March 2013 169 80–244 ng/mL 409 <496mU/L
March 2014 193 87–399 ng/mL 421 <496mU/L
June 2014 254 87–399 ng/mL 509 <496mU/L
January 2015 234 87–399 ng/mL 406 <496mU/L
January 2016 36 94–506 ng/mL 391 <496mU/L
November 2016 784 <496mU/L
February 2017 232 101–576 μg/L
667 (0′)
652 (30′) <496mU/L 1.80–0.79–0.28 (60
′)–0.19 (120′)–2.03 μg/L
November 2017 346 101–576 μg/L 675 <496mU/L
(a) (b)
Figure 5: Pituitary MRI scans of the proband’s ﬁrst cousin (case 5), showing a normal pituitary at the age of 9 (a), and three years later, a
3mm microadenoma became visible in her pituitary gland (b).
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of his pituitary function being normal. One year later, his
IGF-1 was found within normal range (215 nmol/L [94–
252]). The proband’s mother, an obligate AIP mutation car-
rier, was diagnosed with a spinal ependymoma and died at
the age of 45. The proband’s at-risk second cousin, untested
for AIP mutation, died of Hodgkin’s lymphoma.
9. Patient Comments
In order to gain some insight into the experiences of patients
and carriers, we asked three patients (case 1, case 2, and
case 5) and one unaﬀected carrier (subject III.b) questions
about the impact of having this mutation.
Case 1 and case 2 raised three main issues:
(1) The Impact of Headaches. Both patients reported
headaches prior to the treatment. “I suﬀered daily
headaches which were something I was unaccus-
tomed to.”
Even after treatment, case 2 reports that the head-
aches have returned but he has found ways to
manage this. “Over the past 15 years…daily head-
aches have returned and become worse over
time….Rubbing of the temples and cold hands help
manage the pain. I know these episodes pass with
time and this gives me reassurance while experienc-
ing them.”
(2) Improvement after Treatment. In both cases, the
patients report signiﬁcant improvement after treat-
ment. “Treatment … was excellent and the results
almost instant.”
Following treatment, case 1 felt he was soon at “full
physical capacity.” Case 2 noticed that after surgery,
“lethargy was no longer an issue” and although the
headaches persisted, they were “no longer a daily
recurrence” and would only become intense “under
high-pressure conditions such as underwater or
during a ﬂight.”
(3) Future Choices and Vigilance. Overall, both patients
agreed that, although they remain vigilant for symp-
toms, their previous diagnoses and genetic status will
not aﬀect the choices they make in the future. The
patients felt like they “could not be in safer hands”
and felt conﬁdent that the condition was “entirely
treatable and manageable.”
Therefore, being equipped with knowledge about
symptoms and having the support from their medical
team, they do not have any signiﬁcant concerns about
the future “…knowing symptoms and the capacity to
diagnose much quicker means future issues with
passing the mutated gene on through the bloodline
is no longer a concern.”
“…having these issues has not aﬀected the choices I
have made for my future…I have a good understand-
ing of my own capabilities and boundaries.”
From the interview of subject III.b (unaﬀected carrier)
and his 12-year-old daughter (case 5), two main themes
emerged:
(1) Emotional and Behavioural Impact of Having a
Genetic Mutation. In terms of emotional impact, sub-
ject III.b was initially disappointed to ﬁnd out that he
was a carrier of the AIP mutation, but not surprised.
He also indicated that this knowledge was beneﬁcial.
“It was pretty disappointing to ﬁnd out, but much
better to know than to not know.”
Case 5 had a similar reaction. Initially, she was wor-
ried, but this gave way to positive feelings related to
the beneﬁt of having information regarding the
genetic predisposition. What is particularly positive
is that over time, case 5 has come to terms with her
genetic status. “At ﬁrst I was worried and upset and
I didn’t really understand what it was…Overall I
think it is good, so I can get tested and if I have any
issues they will be discovered early in the process
and hopefully any treatment will be smaller”. “I have
got more used to it.”
In terms of behavioural impact, subject III.b felt that
ﬁnding out that he was a carrier had very little impact
on behaviour. “In some ways it has made me more
aware/conscious of my health, but I wouldn’t say it
has driven too much behavioural change.”
However, once it was established that one of his chil-
dren was a carrier (case 5), “the impact was more sig-
niﬁcant”. “Since my daughter was conﬁrmed as a
carrier, we have been more aware and conscious of
symptoms that may be connected to the condition.
For example, she suﬀers fromheadaches andwewatch
themmuchmore carefully then we would otherwise.”
(2) Routine Monitoring. Subject III.b commented on the
“inconvenience of annual blood tests and the occa-
sional scan,” but overall he felt that it was “not too
demanding” and that it was important to “continue
with the testing regime and make sure that any future
generations of the family are informed and tested.”
However, subject III.b did remark that the “testing
routine is quite upsetting for a young child.” This
was conﬁrmed by her 12-year-old daughter (case 5)
who commented on her dislike for the blood tests
and scans. However, even though she dislikes the rou-
tine monitoring, she understands how important it is.
“I understand the importance of the tests even if I
don’t like them…I am also getting better at man-
aging the blood test.”
10. Discussion
This large English kindred illustrates some key aspects and
management challenges in AIP mutation-positive FIPA.
The investigation, treatment, and follow-up of each case
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presented a number of unique challenging scenarios, provid-
ing learning opportunities and insights into clinical practice
and genetic counselling, raising also some important ques-
tions that we aim to answer based on published data and
our own experience with this condition [8, 16].
10.1. Diagnosis. The diagnosis of PAs can be delayed and is
frequently made incidentally [2]. The diagnosis of the pro-
band’s case was delayed for months, initially interpreted in
the context of grief. The fact is that he was remarkably
hypothyroid and hypoadrenal at diagnosis and at risk of a
life-threatening adrenal crisis. In contrast, his brother pre-
sented with headaches, but his diagnosis was faster due to
the PA family history. This highlights the importance of
patient and family member education for symptoms and
the family history value in pituitary diseases. Age at diagno-
sis is lower in the second generation of FIPA families likely
due to an increase in patient education and not in genetic
anticipation [17].
Case 3 and case 5 illustrate the challenges associated with
prospective diagnosis in AIP mutation carriers. Considering
the high frequency of pituitary incidentalomas in the general
population, up to 14–22% in radiological and autopsy studies
[2], it is diﬃcult to establish whether these lesions would
behave diﬀerently from sporadic incidentalomas [18].
10.2. Headache. Headache is a major problem in patients
with PAs, particularly in acromegaly [19, 20]. The presence
of headache depends on PA subtype, size, tumour activity,
cavernous sinus invasion, and predisposition for headache
[20]. Both macroadenomas and microadenomas are linked
with this problem [19, 21, 22]. In Cushing’s disease series,
nearly 30% of patients with microadenomas had headaches
[21], whereas headaches are reported in 50% of acromegalic
patients with microadenomas [23]. Headache features are
variable, but most cases have chronic headache (46%) or epi-
sodic migraines (30%) [20]. Hypophysectomy may improve
headaches in half of the cases, but can also paradoxically
exacerbate them in 15% [20], or have no eﬀect [24]. Somato-
statin analogues may improve acromegaly-associated head-
aches in up to two-thirds of the patients; dopamine agonists
may improve headaches in 25% but also exacerbate them in
21% of cases [20, 25–27].
Unfortunately, the ﬁst surgery, short-acting octreotide, or
cabergoline did not resolve case 2’s headache, which was
improved after the second TSS. Case 3 and case 5 also suf-
fered from headache, and it is unclear if this is attributable
to the small PAs or coincidental. Headache is common in
the general population, with more than 50% of adults
experiencing headache [28]; thus, patients with PAs may well
have headache unrelated to their PA.
10.3. Double Adenoma. Case 4 had two diﬀerent PAs con-
comitantly consisting of two diﬀerent cell types. The possibil-
ity for multifocal PAs must be taken into account at diagnosis
and during follow-up of any patient with germline AIPmuta-
tions, as all the anterior pituitary cells are haploinsuﬃcient
for AIP and therefore at risk. Multifocal PAs are rare in spo-
radic settings but have been described in patients with the
Carney complex or MEN1 [29, 30]. In a surgical series of
117 patients with PAs, only 3 cases (2.6%) had double PAs
and 1 had concomitantly a somatotrophinoma and a silent
mammosomatotroph adenoma, whereas in the other 2 cases,
coexistent lactotroph and null-cell adenomas were noted.
These 3 cases were negative for AIP or MEN1 mutations
[31]. Another series including 600 surgical cases reported
only 4 cases with double PAs (0.7%), conﬁrmed histologically
as GH-secreting PA plus gonadotroph PA in 2 cases and con-
comitant somatotrophinomas in other 2 patients [32]. A
series of autopsies report double adenoma prevalences rang-
ing between 0.9 and 2% in subjects with PAs [31, 33]. Double
PAs can have a similar hormonal proﬁle, more commonly
ACTH [34–36] or GH [32], but diﬀerent hormone-secreting
double PAs seem to occur more frequently [31, 37]. In a large
series, MEN1 patients had more frequently multiple PAs in
comparison to non-MEN1 patients (4% versus 0.1%) [38].
Apart from our case [9] (one in 144 AIP mutation-positive
PA patients [8], prevalence 0.7%), double PAs have been
reported in an AIP mutation-positive patient where no sur-
gery was performed so histology is not available [39]. GH-
and prolactin-cosecreting PAs due to AIP mutations are fre-
quent (23.9% in our cohort [8]), but GH and prolactin secre-
tion from 2 distinct PAs is unique in our case 4. Thus,
multifocal PAs should raise suspicion for familial disease.
10.4. Rathke’s Cyst. Case 3 displayed a small Rathke’s cyst
which regressed within 5 years. Rathke’s cysts arise from
remnants of the embryologic Rathke’s pouch and are found
in 12–33% of normal pituitary glands in routine autopsies
[40], 2-3 times more frequent in women [41]. In a cohort
of 29 patients with symptomatic Rathke’s cyst managed with
surveillance, spontaneous involution was described in 31%
and headaches were resolved spontaneously in 5 out of 7
cases [42]. Case 3’s headaches continued despite the Rathke’s
cyst regression, so we cannot attribute this symptom to
Rathke’s cyst. Rathke’s cysts have not been described in
patients with AIP mutations apart from our case 3 [8].
10.5. Size of the Pituitary Gland in Teenager Females.
Another challenge raised by case 3 is the pituitary volume
in teenagers, especially females. Pituitary volume is normally
increased in adolescents and young women. Neuroradiologi-
cal series reported that 25–50% of healthy young women
have a convex superior pituitary contour, and pituitary
height more than 7, 8, or 9mm can be found in 6.2%, 1.1%,
and 0.5%, respectively [43].
10.6. GH Excess Diagnosis in Adolescence. GH excess diagno-
sis is challenging in adolescence at the peak of pubertal
growth and for girls also when hormonal contraceptives are
used [44, 45]. GH suppression after OGTT is gender and
pubertal stage speciﬁc, with higher GH nadir in puberty
and in girls: a study reported that the GH nadir is highest
in Tanner stage 2-3 girls (1.57 ng/mL) and lower in other
pubertal stages (0.64 ng/mL) or in boys (0.50 ng/mL) [45].
These GH dynamic testing cut-oﬀs are diﬀerent from those
in adults [46]. Lack of GH nadir cut-oﬀs on OGTT according
to sex and pubertal stage makes the practical use of this test
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limited in children and adolescents. Moreover, delayed or
accelerated puberty can result in a mismatch between the
measurable IGF-1 and the chronological IGF-1 reference
range [47]. The recognition of oral contraceptive use in
females carrying AIP mutations is important for the inter-
pretation of IGF-1 results, as they interfere with IGF-1
levels. Oestrogens lower IGF-1 levels, which explains why
females have lower IGF-1 than men [48]. In women with
mild acromegaly, oral contraceptives may normalise IGF-1
and reduce metabolic and body compositional eﬀects of
GH excess [48, 49]. In case 3, we found normal IGF-1.
The eﬀects on IGF-1, prominent with oral oestrogens, are
minimal with transdermal formulations [50]; therefore, we
exclude the inﬂuence of contraceptive patches (containing
a combination of ethinyl oestradiol and norelgestromin)
in her IGF-1 measurements.
10.7. Mild Abnormalities in Asymptomatic Carriers. One AIP
mutation carrier in our kindred, the proband’s male cousin
(III.b), who has no symptoms of acromegaly and has normal
MRI, was found with slightly increased IGF-1 (1.03×ULN),
but his GH nadir on OGTT was 0.28μg/L, and a repeated
IGF-1 later was normal. Intermittent IGF-1 elevations, often
with normal GH dynamic testing, with normal MRI have
been seen in asymptomatic AIP mutation carriers in our
cohort [8] and also reported by others [51]. Subtle abnormal-
ities in the somatotroph axis in the absence of symptoms are
typical in the Carney complex and related to somatotroph
hyperplasia [52, 53].
In AIP mutation carriers, these mild biochemical abnor-
malities may be due to very small PAs not visible on MRI
or due to somatotroph hyperplasia, described in a few AIP
mutation-positive cases [54, 55]. Some of these cases do not
fully fulﬁl the established diagnostic criteria for acromegaly
and may represent a unique entity in the natural history of
this condition.
10.8. Hyperprolactinaemia. The above considerations are
valid for asymptomatic individuals carrying AIP mutations
with mild hyperprolactinaemia, in whom its aetiology might
be challenging to determine. Hyperprolactinaemia is com-
mon, due to physiological changes (stress, food ingestion,
exercise, coitus, chest stimulation, sleep, lactation, and
pregnancy), diseases (epilepsy, renal failure, cirrhosis,
chest trauma, hypothyroidism, and polycystic ovary syn-
drome), or medications [56]. The relevance of mild
hyperprolactinaemia, when macroprolactinaemia is ruled
out, can be challenging when found concomitantly with
a 3mm PA, as in case 5. As hyperprolactinaemia may
have signiﬁcant inhibitory eﬀects on puberty [57], careful
follow-up is needed.
10.9. MRI Scanning during Carrier Follow-Up. Another point
to consider in case 5 is the question of MRI scanning in pae-
diatric settings. We usually suggest to perform the ﬁrst MRI
in AIP mutation carriers, if clinical and biochemical assess-
ments are previously normal, at the age of 10 when children
are reasonably expected to undergo an MRI without sedation
[16]. The youngest known case with an AIPmutation and PA
showed signs of tall stature at the age of 3 and was diagnosed
with a macroadenoma with extensive extrasellar extension
[58]. Our patient had the MRI at the age of 9, because of
headaches, and showed no abnormality. MRI was repeated
3 years later due to worsening headache, and a pituitary
microadenoma was seen. To our knowledge, this case is the
ﬁrst reported AIP mutation-positive patient presenting with
a PA not seen on the ﬁrst screening and emerging during
imaging surveillance.
10.10. Extrapituitary Diseases. The proband’s mother, an
obligate AIP mutation carrier, died from a spinal ependy-
moma. There are reports in the literature of 11q13 abnormal-
ities in ependymomas [59], and there is also a report of a
MEN1 patient (MEN1 is located at 11q13, like AIP) with an
ependymoma [60]. Ependymoma has not been described in
other AIP mutation-positive FIPA families [8]. We do not
have access to the spinal ependymoma tissue; thus, we could
not study the expression or loss heterozygosity to aﬃrm an
association with the AIP mutation. In our AIP mutation-
positive patient cohort, we have eleven cases with extrapitui-
tary neoplasms: two females with breast cancer, three cases
with gastrointestinal stromal tumour (two in the same
family), two related cases with meningioma [61], one with
non-Hodgkin’s lymphoma, one male with osteosarcoma
and a colon neuroendocrine tumour [8], one with glioma
(loss of heterozygosity of the AIP mutant locus was not
present [62]), and a 21-year-old female carrier with a
lipoma (unpublished). LOH at 11q13 with loss of AIP
expression has also been reported in an adrenocortical car-
cinoma in a patient aﬀected by a germline AIP mutation
[63], but Chr11q loss of heterozygosity is common in
adrenocortical cancers [8]. Other anomalies have also been
detected in AIP mutation carriers, such as hydrocephalus
and aneurysms [64].
10.11. PA Features in AIP Mutation-Positive Patients. In AIP
mutation-positive kindreds, GH-secreting (45.7%) and GH-
and prolactin-cosecreting (23.9%) PAs are the most common
types [8]. Gigantism is particularly frequent, representing
over a third of AIP mutation-positive patients [8, 10]. Vari-
ability in PA subtypes is seen in our kindred. AIP
mutation-positive patients typically have PAs in the second
decade (mean age at diagnosis between 18 and 24 years),
and almost all are diagnosed before the age of 40 [8, 65, 66].
In our kindred, four cases were diagnosed before the age of
18, and case 4 was diagnosed at the age of 27 when stopping
an oral contraceptive, so it might have been causing
symptoms earlier. Patients with PAs associated with AIP
mutations present earlier in life in comparison with sporadic
or AIP-negative FIPA cases and tend to have more aggressive
disease. However, not all AIPmutation-positive FIPAs have a
rapidly growing and aggressive phenotype. In this kindred,
the PAs were not particularly aggressive.
10.11.1. What Is the Penetrance of AIP Mutation-Positive
FIPA Kindreds?Analysis of large kindreds suggested a hetero-
zygous autosomal dominant inheritance pattern with incom-
plete penetrance in FIPA due to AIP mutations [7]. The
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penetrance of PAs in the kindred here reported is 36%, with 5
PA cases out of 14 members harbouring AIPmutations. Pen-
etrance of PAs has been estimated to range between 15 and
30% [10]. Based on 3 extensively screened large families in
our cohort, we found a penetrance of 22.7%, but when cases
diagnosed prospectively were excluded, the penetrance was
only 12.5%, highlighting the relevance of screening for appar-
ently unaﬀected AIP mutation carriers [8]. The published
data suggest that the mutation type (truncating versus mis-
sense) does not inﬂuence the overall penetrance, although it
might inﬂuence the age of penetrance [8]. A germline FGFR4
variant was excluded as a possible disease-modifying-disease
gene, and GNASmutations are not present in AIPmutation-
positive PAs [8]. Variable penetrance could be explained by
other, currently unknown, genes inﬂuencing disease mani-
festation, as well as by other factors, such environmental
inﬂuences [51, 67, 68].
10.11.2. Which Patients with PAs Should Be Tested for AIP
Mutations? No consensus guidelines in terms of genetic
screening for AIP mutations and surveillance and manage-
ment of AIP mutation asymptomatic carriers are available
yet in this setting. Rather, expert recommendations are
available on the basis of the literature. Patients with PAs that
should be tested for AIP mutations include as follows:
(1) Patients with a diagnosis of FIPA, that is, patients
with a PA who have a family history of PA and do
not have clinical or genetic features of any syndromic
disease. Approximately 20% of all FIPA families have
AIPmutations, and this rises to 40% if members have
only somatotrophinomas and to almost 100% if two
or more members have childhood-onset somatotro-
phinomas [10].
(2) Patients with macroadenomas diagnosed before the
age of 30, particularly those secreting GH and/or pro-
lactin, who do not have an apparent family history of
PAs. A signiﬁcant proportion of these, approximately
12%, has AIP mutations [13, 69]. The lack of family
history can be due to limited family history informa-
tion, relatively low penetrance of PAs inAIPmutation
carriers, or de novo AIP mutations [16], although
only two cases of de novo mutations have been
reported [70, 71].
(3) Patients with a PA diagnosed before the age of 18
years. Up to 20% of these, usually somatotrophino-
mas or prolactinomas, have an AIPmutation. In pae-
diatric Cushing’s disease or NFPA, the chances of
ﬁnding AIP mutations are lower, but still genetic
testing is advocated [11, 13, 16, 71].
(4) Patients with multifocal PAs, particularly in the case
of GH and/or prolactin hypersecretion. Double PAs
have been only reported twice in the AIP mutation-
positive setting. Until more data is available, it is
reasonable to test patients with double or multiple
PAs for AIP mutations, particularly in the absence
of syndromic features.
10.11.3. How to Manage AIP Mutation-Positive Patients and
Carriers?
(1) Patients with FIPA due to AIP mutations who pres-
ent clinically should be treated as any sporadic PA
depending on their PA subtype and disease extension
in accordance to current guidelines [18, 46, 72–74].
However, these tumours can be larger and more inva-
sive and often respond poorly to therapy, requiring
multimodal approach [10].
(2) First-degree family members (parents, children,
and siblings) of FIPA probands should be oﬀered
genetic testing for their familial AIP mutation
following genetic counselling. In individuals with
germline AIP mutations but no family history,
referral of ﬁrst-degree relatives is appropriate for
cascade screening.
(3) AIP mutation-positive individuals require genetic
counselling. Autosomal dominant inheritance, avail-
able data on PA penetrance, pituitary disease mani-
festations, the need for clinical screening and
follow-up, and the carrier AIP status of their children
should be explained to patients and carriers.
(4) AIP mutation carriers should have baseline testing
including clinical examination, biochemical testing,
and pituitary MRI. Prolactin and IGF-1 should be
measured routinely, and in selected cases, GH on
OGTT is required. Although the disease usually starts
towards the second part of the ﬁrst decade, there are
cases reported earlier [58]. We recommend genetic
screening by the age of 2 years, as other groups
[10]. AIP mutation carriers should be assessed in
terms of height and weight, height velocity, pubertal
development, and baseline pituitary tests. Clinical
assessment might start at the age of 3 years. Prolactin
measurement should start early, since growth retar-
dation is present only in a minority of children with
prolactinomas [75, 76], thereby limiting the sensitiv-
ity of auxological evaluation, which is of utmost
importance for early detection of GH excess. Thus,
we recommend that prolactin and IGF-1 measure-
ments should start by the age of 3 years and be
repeated routinely on a yearly basis. In young
children, unless biochemical or clinical evidence of
disease, baseline MRI can be delayed until old enough
to be performed without anaesthesia, usually 10
years, also because most childhood-onset cases start
above this age [64].
(5) AIPmutation carriers who are found to have clinical,
hormonal, and radiological signs of PAs at baseline
assessment should be treated according to the current
guidelines [18, 46, 72–74].
(6) Family members who are found to be AIP mutation
carriers but do not have clinical, hormonal, or
radiological signs of PAs at baseline assessment
should be followed with clinical and biochemical
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assessment. Children and young adults can be eval-
uated clinically and biochemically on a yearly basis
and instructed to seek assistance before any signs
of pituitary disease. Follow-up pituitary MRI can
be repeated every 5 years. Duration of regular
screening is currently an open question. The major-
ity of PAs are diagnosed before the age of 30–40
years [11]; so, it is conceivable to decrease and even
stop screening frequency beyond this age if routine
evaluations are consistently normal. Ending the
follow-up can be considered in older patients, given
the low probability of detecting PAs after the ﬁfth
decade of life [8], although this is not our current
practice. Our oldest AIP mutation-positive patient
presented with apoplexy due to large macroade-
noma at the age of 66 years, while the oldest AIP
mutation-positive patient was identiﬁed prospec-
tively with a PA at the age of 69 years.
10.11.4. How to Test for AIP Mutations? More than one
hundred AIP gene variants have now been described, includ-
ing insertions/deletions, single-nucleotide polymorphisms,
nonsense and missense mutations, duplications, promoter
and splice site mutations, and large genomic deletions. Most
disease-causing mutations lead to truncated protein (around
70%), and a few hotspots are identiﬁed to date (R304∗,
R271W, and R81∗) [8]. Sequence analysis of AIP exons,
exon-intron junctions, and promoter region will detect
approximately 90% of AIP mutations. However, 10% of
abnormalities in theAIP gene in FIPA families are due to large
deletions, like in our kindred, which can be detected byMLPA
[15, 16]. Therefore, AIP gene sequence analysis followed by
MLPA is the recommended testing method.
When a rare and/or a new AIP variant is detected, careful
assessment should be taken to understand if that variant is
likely to cause disease or it might be a nonpathogenic variant,
as this is of major importance for genetic counselling and for
deciding whether family members require genetic screening.
There are diverse forms to predict the pathogenicity of an
AIP variant, such as segregation of that variant with the
disease, its frequency in the general population, in silico pre-
dictions, in vitro functional studies, loss of heterozygosity
demonstration, and conservation across species [64]. Both
the International Agency for Research on Cancer (IARC)
and the American College of Medical Genetics and Genomics
(ACMG) suggest a 5-tier system to characterise variants:
pathogenic, likely pathogenic, uncertain signiﬁcance, likely
benign, and benign [77, 78].
10.11.5. Beneﬁts of AIP Genetic Testing. Genetic and clinical
screening has been shown to identify an unexpectedly high
proportion, 20–25% of apparently unaﬀected carriers with
PAs [8]. Genetic test for AIP mutations in individuals at risk
and subsequent clinical screening in apparently unaﬀected
AIPmutation carriers can result in early diagnosis and treat-
ment of possibly aggressive PAs. Family members who do
not carry AIP mutations will be relieved from follow-up.
Psychological impact of long-term surveillance needs to be
considered, and AIP mutation carriers should be reassured
of the benignity and low penetrance of PAs but understand
the beneﬁts of early detection in case of disease. The lack of
compliance with the long-term follow-up is often an issue,
partially due to the low penetrance and benign nature of
the disease.
11. Conclusions
The clinical and genetic characteristics of FIPA patients have
been studied extensively over the last years. Current data sug-
gest that genetic screening for AIP mutations will reveal on
average 20% of FIPA families harbouring an AIP mutation,
but the detection range is wide depending on the speciﬁc
studied population, varying from 3% in unselected popula-
tions to almost 100% if two or more childhood-onset
somatotrophinomas are identiﬁed in the same family. Pro-
spective screening of family members can identify presymp-
tomatic disease. Further research is needed to identify novel
genes causing FIPA. The genetic counselling and clinical
management of FIPA cases require a multidisciplinary
approach which hopefully will improve prognosis and out-
comes in the future. The kindred described here aid us to
understand some of the clinical, diagnostic, and management
challenges associated with AIPmutation-positive PAs, and it
allows us to review essential aspects associated with the
genetic diagnosis and screening of this setting.
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Patient Comments. Minor amendments were made to patient
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